{"id":"https://openalex.org/A5020143735","orcid":"https://orcid.org/0009-0008-8159-4109","observed_orcids":["https://orcid.org/0009-0008-8159-4109"],"display_name":"Michele Riggen","raw_author_names":["Michele Riggen"],"full_name":"Michele Riggen","works_count":3,"cited_by_count":27,"summary_stats":{"2yr_mean_citedness":2.5,"h_index":2,"i10_index":1},"ids":{"openalex":"https://openalex.org/A5020143735","orcid":"https://orcid.org/0009-0008-8159-4109","observed_orcids":["https://orcid.org/0009-0008-8159-4109"]},"affiliations":[{"institution":{"id":"https://openalex.org/I4210087505","ror":"https://ror.org/003m2d425","display_name":"United BioSource Corporation (United Kingdom)","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210087505"]},"years":[2026]}],"last_known_institutions":[{"id":"https://openalex.org/I4210087505","ror":"https://ror.org/003m2d425","display_name":"United BioSource Corporation (United Kingdom)","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210087505"]}],"topics":[{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","count":3,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11412","display_name":"Genetic and Kidney Cyst Diseases","count":2,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11465","display_name":"Drug-Induced Hepatotoxicity and Protection","count":2,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11649","display_name":"Pharmaceutical industry and healthcare","count":1,"subfield":{"id":"https://openalex.org/subfields/2910","display_name":"Issues, ethics and legal aspects"},"field":{"id":"https://openalex.org/fields/29","display_name":"Nursing"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","count":1,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"topic_share":[{"id":"https://openalex.org/T11412","display_name":"Genetic and Kidney Cyst Diseases","value":1.88e-05,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","value":1.18e-05,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11465","display_name":"Drug-Induced Hepatotoxicity and Protection","value":8.8e-06,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11649","display_name":"Pharmaceutical industry and healthcare","value":7.7e-06,"subfield":{"id":"https://openalex.org/subfields/2910","display_name":"Issues, ethics and legal aspects"},"field":{"id":"https://openalex.org/fields/29","display_name":"Nursing"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","value":5.3e-06,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"x_concepts":[{"id":"71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","score":0.8587999939918518},{"id":"126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","score":0.543701171875},{"id":"177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","score":0.3659592866897583},{"id":"120665830","wikidata":"https://www.wikidata.org/wiki/Q14620","display_name":"Optics","score":0.0},{"id":"121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","score":0.0}],"counts_by_year":[{"year":2022,"works_count":1,"oa_works_count":1,"cited_by_count":0},{"year":2023,"works_count":0,"oa_works_count":0,"cited_by_count":2},{"year":2024,"works_count":0,"oa_works_count":0,"cited_by_count":7},{"year":2025,"works_count":1,"oa_works_count":1,"cited_by_count":9},{"year":2026,"works_count":1,"oa_works_count":1,"cited_by_count":9}],"display_name_alternatives":["Michele Riggen"],"block_key":"m riggen","works_api_url":"https://api.openalex.org/works?filter=author.id:A5020143735","awards_count":0,"awards_api_url":"https://api.openalex.org/awards?filter=investigators.author.id:A5020143735","updated_date":"2026-11-12T13:17:38","created_date":"2022-05-05T00:00:00"}